Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3042]

Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory...

Prof Walter Fiedler - University of Hamburg, Hamburg, Germany

$Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia ( Prof Walter Fiedler - University of Hamburg, Hamburg, Germany )$

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy...

Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM ( Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China )

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

HORIZON update: Using melflufen to treat RRMM patients refractory to...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

$HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )$

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin...

Michael Fuchs - University Hospital of Cologne, Cologne, Germany

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma ( Michael Fuchs - University Hospital of Cologne, Cologne, Germany )

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Safety and efficacy of escalating doses of Hu5F9-G4 with rituximab in patients with R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Using bioinformatics and genomics to treat AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

The changing landscape of AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions

Dr Joel Neal - Stanford University, Stanford, USA

Anti-tumour activity of TAK-788 in NSCLC patients with EGFR exon 20 insertions ( Dr Joel Neal - Stanford University, Stanford, USA )

Comment: Enfortumab vedotin is an effective therapy and important development...

Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak

Comment: Enfortumab vedotin is an effective therapy and important development for urotherial cancer patients ( Dr Robert Dreicer, Dr Richard Schilsky and Prof Daniel Petrylak )

Novel methods of drug testing and biopsy in India

Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India

Novel methods of drug testing and biopsy in India ( Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India )

Cutting-edge cancer care at the Miami Cancer Institute

Dr Miguel Villalona - Miami Cancer Institute, Miami, USA

Cutting-edge cancer care at the Miami Cancer Institute ( Dr Miguel Villalona - Miami Cancer Institute, Miami, USA )

More from ecancer